drugset / Trial / NCT00461981
A Phase 2 Study to Evaluate Immune Responses of FluMist®
RandomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to describe the level of serum antibody and cellular immune responses conferred by FluMist and TIV against influenza virus strains.
Timeline
- Start
- 2007-05
- Primary completion
- 2007-12
- Completion
- 2008-02
Outcome
Mixed primary results
registry analysis (unspecified test); FluMist, Influenza Virus Vaccine Live vs TIV, Trivalent Inactivated Influenza Virus Vaccine; Rate differences -60.6 (95% CI -79.7 to -31.7) NCT00461981 ↗
registry analysis (unspecified test); FluMist, Influenza Virus Vaccine Live vs TIV, Trivalent Inactivated Influenza Virus Vaccine; Rate differences 44.2 (95% CI 12.0 to 67.8) NCT00461981 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FluMist | Vaccine | 0.5 ml | Intranasal |
| Comparator | Trivalent Inactivated Influenza Virus Vaccine | Vaccine | 0.25 ml | Intramuscular |
Indications
No indication recorded.